Curia wins 2023 Frost & Sullivan Customer Value Leadership Award

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Curia recognized for providing a best-in-class customer experience in the CRDMO industry through its innovative approach and growth strategy

ALBANY, N.Y., June 29, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a Best Practices Customer Value Leadership Award in the CRDMO industry by Frost & Sullivan.

“We are very honored to be recognized with this award, which underlines the hard work and dedication of all of our employees to delivering quality and reliability when serving our customers,” said Philip Macnabb, CEO, Curia. “We remain steadfast in our noble purpose of improving patients’ lives, a mission that begins with our commitment to creating value for our customers.”

Frost & Sullivan noted in its report that the company’s rebrand from AMRI to Curia in 2021 put a focus on science at the center of its brand identity, highlighting a pledge to help customers advance “from curiosity to cure.” Curia has evolved over time to offer a comprehensive range of services from drug discovery through development to manufacture of both drug substance and drug product for pharmaceutical and biologics companies. The award recognizes how Curia seeks out innovative solutions by using the latest technologies to efficiently move products from discovery to development to commercial scale to accelerate speed to market for its customers. This continuous commitment to serve unspoken market needs and deliver end-to-end solutions for customers has positioned it as an industry leader.

“Curia has built its reputation by offering a best-in-class customer ownership and service experience. The company surveys clients to gauge their overall satisfaction and ensure that it is upholding the highest standards,” said Unmesh Lal, director, Healthcare & Life Sciences, Frost & Sullivan.

Each year, Frost & Sullivan employs a rigorous evaluation, measuring business and customer impact, to identify companies that consistently innovate to meet their customers’ needs while navigating new challenges and opportunities. The winner is recognized for providing a superior customer experience for overall price, performance and quality.

About Curia
Curia, formerly AMRI, is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s nearly 4,000 employees at 29 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

About Frost & Sullivan
Frost & Sullivan is the Growth Pipeline Company™. We power our clients to a future shaped by growth. Our Growth Pipeline as a Service™ provides the CEO and the CEO’s growth team with a continuous and rigorous platform of growth opportunities, ensuring long-term success. To achieve positive outcomes, our team leverages over 60 years of experience, coaching organizations of all types and sizes across 6 continents with our proven best practices. To power your Growth Pipeline future, visit Frost & Sullivan at http://www.frost.com.

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Staff

Recent Posts

MedsEngine Achieves High Blood Pressure Control In Less Than Two Office Visits

DAYTON, Ohio--(BUSINESS WIRE)--MedsEngine LLC, a provider of chronic disease management software, presented its findings on…

57 minutes ago

Clarivate and CAPES Expand Landmark Partnership to Power Research and Innovation Across Brazil

New five-year agreement delivers critical academic and life sciences insights into more than 400 institutions,…

60 minutes ago

Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub

Montreal, Quebec--(Newsfile Corp. - June 2, 2025) -  Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE:…

3 hours ago

TMCI Deadline: Rosen Law Firm Urges Treace Medical Concepts, Inc. (NASDAQ: TMCI) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a…

19 hours ago

Introducing Tempus One in the EHR with Integrated Guidelines

The AI-enabled clinical assistant is available to query patient data across the EHR as well…

22 hours ago

Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis

33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC)…

22 hours ago